Gut hormones, incretin mimetics and gliptins: New understanding and novel therapies in type 2 diabetes

Primary Care Diabetes

Volumn 1, Issue 2, 2007, Pages 103-105

  Munro, Neil M ^a   Levy, Jonathan C ^b  

^a Capelfield Surgery   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

DPP 1V inhibitors; Gliptins; GLP 1 analogues agonists; Incretin mimetics; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN;

ARTICLE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; SECRETION;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN;

EID: 34249677406     PISSN: 17519918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcd.2007.04.003     Document Type: Article

References (20)

1. Drucker D.J. Unraveling the complexities of gut endocrinology. Nat. Clin. Pract. Endocrinol. Metab. 3 4 (2007) 317
2. Elrick H., Stimmler L., Hlad Jr. C.J., et al. Plasma insulin response to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab. 24 (1964) 1076-1082
3. Perley M.J., and Kipnis D.M. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J. Clin. Invest. 46 (1967) 1954-1962
4. Nauck M., Stockmann F., Ebert R., and Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986) 46-52
5. Rudovich A., Kaiser S., Engeli S., and Pfeiffer A.F.H. Gastric inhibitory polypeptide receptors are present in human subcutaneous adipose tissue: effects of central obesity and weight loss. Programme and Abstracts of the European Association for the Study of Diabetes 41st Annual Meeting. September 12-15, Athens, Greece (2005) (Abstract 549)
6. Vilsboli T., and Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47 3 (2004) 357-366
7. Triplitt C., Wright A., and Chiquette E. Incretin mimetics and dipeptidyl peptidase-1V inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy 26 3 (2006) 360-374
8. Grant S.F., Thorleifsson G., Reynisdottir I., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38 3 (2006) 320-323
9. Eng J., Kleiman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267 11 (1992) 7402-7405
10. Levy J.C. Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes. Diabetic Med. 23 s1 (2006) 14-19
11. Orskov C., Poulson S.S., Moller M., and Holst J.J. Glucagon-like peptide receptors in the subfornical organ and the area postrema are accessible to circulating glucagons-like peptide 1. Diabetes 45 6 (1996) 832-835
12. Idris I., and Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabet. Obesity Metab. 9 2 (2007) 153-165
13. Chyan Y.-J., and Chuang L.-M. Dipeptidyl peptidase-IV inhibitors: an evolving treatment for type 2 diabetes from the incretin concept endocrine. Metab. Immune Drug Discov. 1 1 (2007) 15-24
14. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53 9 (2004) 2181-2189
15. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycaemic control over 30 weeks in sulphonylurea treated patients with type 2 diabetes. Diabet. Care 27 11 (2004) 2628-2635
16. DeFronzo R.A., Ratner R., Han J., Kim D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycaemic control over 30 weeks in metformin treated patients. Diabet. Care 28 (2005) 1092-1100
17. Kendall D.M., Riddle M.C., Rosentock J., et al. Effects of exenatide (exendin-4) on glycaemic control over 30 weeks in patients treated with metformin and a sulphonylurea. Diabet. Care 28 (2005) 1083-1091
18. Dejager S., Lebault A., Couturier A., and Schweizer A. Sustained reduction in HbA1cs during one-year treatment with vildagliptin in patients with type 2 diabetes. Program and Abstracts of the American Diabetes Association 66th Scientific Sessions. June 9-13, Washington, DC (2006) (Abstract 120-OR)
19. Riddle M.C., Henry R.R., Poon T.H., et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabet. Metab. Res. Rev. 22 6 (2006) 483-491
20. Fineman M.S., Shen L.Z., Taylor K., Kim D.D., and Baron A.D. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabet. Metab. Res. Rev. 20 5 (2004) 411-417